Dexcom (DXCM) stock is down over 40% in Friday's session after the continuous glucose monitoring technology company fell short of revenue estimates for its second quarter and slashed its full-year ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A better-than-expected third-quarter 2024 performance and a series of favorable coverage ...

Two S&P 500 stocks--DexCom and Albemarle--are already on sale for investors to buy in 2025. Dexcom has become the first company to launch a generative AI-powered continuous glucose monitor.

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of $90.00. Don't Miss our Black Friday Offers ...

Carillon Eagle Mid Cap Growth Fund highlighted stocks like DexCom, Inc. (NASDAQ:DXCM), in the third quarter 2024 investor letter. DexCom, Inc. (NASDAQ:DXCM) is a medical device company that ...